Essential Horse Vaccinations in the United States: A Comprehensive Guide

Introduction to Equine Vaccination

Vaccination represents one of the most important preventive health measures available for protecting horses from infectious diseases. Through strategic immunization programs, horse owners can significantly reduce their animals’ risk of contracting serious, potentially fatal diseases that once devastated equine populations. While no vaccine provides 100% guaranteed protection, properly administered vaccination programs dramatically decrease disease incidence, reduce severity when breakthrough infections occur, and contribute to overall herd immunity that protects entire horse populations.

In the United States, horses face exposure to numerous infectious diseases, some of which are endemic (constantly present) throughout the country, while others occur sporadically or in specific regions. Understanding which vaccines your horse needs, why they’re important, and how frequently they should be administered enables you to make informed decisions that optimize your horse’s health while managing costs and minimizing unnecessary interventions.

The American Association of Equine Practitioners (AAEP) provides evidence-based vaccination guidelines that serve as the foundation for equine immunization programs in the United States. These guidelines classify vaccines into two main categories: core vaccines recommended for all horses regardless of location or lifestyle, and risk-based vaccinesrecommended based on geographic location, exposure risk, travel patterns, and specific circumstances.

This comprehensive guide examines each vaccine available for horses in the United States, explaining what diseases they prevent, why vaccination is recommended, who should receive them, and how frequently they should be administered. By understanding the rationale behind vaccination recommendations, you can work with your veterinarian to develop an individualized immunization program that provides optimal protection for your specific horses in your particular circumstances.

Understanding Core vs. Risk-Based Vaccines

Before examining specific vaccines, it’s essential to understand how vaccines are categorized and why this distinction matters.

Core Vaccines

Core vaccines protect against diseases that:

• Are endemic to a region or present at significant levels
• Pose serious health threats with high morbidity (sickness rate) or mortality (death rate)
• Are highly contagious or have efficient transmission routes
• Represent public health concerns (zoonotic diseases affecting humans)
• Have vaccines that are highly safe and effective

The AAEP designates five core vaccines for horses in the United States:

1. Rabies
2. Tetanus
3. Eastern Equine Encephalomyelitis (EEE)
4. Western Equine Encephalomyelitis (WEE)
5. West Nile Virus (WNV)

All horses in the United States should receive these core vaccines regardless of their use, location, or management, with only rare medical contraindications justifying exceptions.

Risk-Based Vaccines

Risk-based vaccines protect against diseases where:

• Geographic distribution is limited to specific regions
• Exposure risk varies based on management, use, travel, or population density
• Disease severity may not justify universal vaccination
• Cost-benefit analysis varies among individual horses

Risk-based vaccines include:

• Influenza
• Equine Herpesvirus (Rhinopneumonitis)
• Strangles
• Potomac Horse Fever
• Botulism
• Anthrax
• Equine Viral Arteritis
• Rotavirus

The decision to use risk-based vaccines should be made individually for each horse based on consultation with your veterinarian, considering your specific circumstances, regional disease patterns, and exposure risks.

Core Vaccines: Essential Protection for All Horses

1. Rabies Vaccine

The Disease: Rabies

Rabies is a fatal viral disease affecting the central nervous system of all mammals, including horses and humans. Once clinical signs develop, rabies is invariably fatal—no treatment exists, and death occurs within days. The disease is caused by a lyssavirus transmitted primarily through the saliva of infected animals, typically via bite wounds.

In horses, rabies clinical signs include:

• Sudden behavior changes (aggression, depression, or anxiety)
• Ataxia (incoordination) and weakness
• Hypersensitivity to stimuli
• Difficulty swallowing and excessive salivation
• Colic-like symptoms
• Progressive paralysis
• Seizures and death

The disease progresses rapidly, typically causing death within 3-10 days after clinical signs appear. The variable presentation often leads to misdiagnosis, with rabid horses sometimes mistaken for having colic, choke, or neurological diseases like EPM or West Nile Virus.

Epidemiology in the United States: Rabies is endemic throughout the continental United States, with wildlife serving as the primary reservoir. Major rabies vectors include:

• Raccoons (Eastern United States)
• Skunks (Midwest and Western states)
• Bats (throughout the country)
• Foxes (certain regions)

Horses typically contract rabies through bites from infected wildlife, though any exposure to saliva from rabid animals (through wounds or mucous membranes) can transmit the virus. Hundreds of rabies cases are confirmed in U.S. livestock annually, with horses representing a significant portion.

Zoonotic risk: Rabies poses serious public health concerns. People exposed to potentially rabid horses (veterinarians, owners, handlers) require post-exposure prophylaxis—an expensive, time-consuming series of injections. Horses showing neurological signs that die or are euthanized before rabies testing must be presumed potentially rabid, necessitating that all exposed people undergo prophylaxis. Vaccinating horses protects both equine and human health.

The Vaccine

Type: Killed (inactivated) virus vaccines

Efficacy: Highly effective when properly administered; provides excellent protection

Administration: Intramuscular injection, typically in the neck or hindquarter muscles

Primary series:

• Foals from vaccinated mares: Initial vaccination at 6 months of age
• Foals from unvaccinated mares or unknown vaccination status: Begin as early as 3-4 months
• Previously unvaccinated adult horses: Single dose provides protection (though some veterinarians administer a booster 2-4 weeks later for maximum protection)

Booster schedule: Annual revaccination required for all horses

Side effects: Generally minimal

• Occasional mild local swelling or soreness at injection site
• Low-grade fever or lethargy (rare)
• Serious adverse reactions extremely rare

Cost: Approximately $25-40 per dose (veterinary exam fees additional)

Why Rabies Vaccination is Essential

1. Fatal disease with no treatment: 100% mortality rate once clinical signs develop
2. Endemic throughout U.S.: Wildlife vectors present everywhere
3. Unpredictable exposure risk: Even horses with limited outdoor access can encounter bats (which enter barns) or other wildlife
4. Zoonotic concern: Protects people working with horses
5. Legal implications: Unvaccinated horses showing neurological signs create complex legal and public health situations
6. Highly effective vaccine: Excellent protection with minimal risk
7. Relatively inexpensive: Low cost for life-saving protection
8. Required in some jurisdictions: Some states, counties, or event venues mandate rabies vaccination

Bottom line: Rabies vaccination is non-negotiable for responsible horse ownership in the United States.

2. Tetanus Vaccine (Tetanus Toxoid)

The Disease: Tetanus

Tetanus, commonly called “lockjaw,” results from toxins produced by the bacterium Clostridium tetani. This organism exists ubiquitously in soil and horse manure as extremely hardy spores that remain viable for decades. When these spores enter the body through wounds (particularly deep puncture wounds with limited oxygen availability), they germinate, multiply, and produce tetanospasmin—one of the most potent biological toxins known.

Tetanospasmin affects the nervous system, blocking inhibitory signals and causing sustained muscle contractions and spasms. Clinical signs include:

Early signs:

• Stiffness and muscle rigidity
• Difficulty chewing and swallowing
• Third eyelid protrusion
• Erect, immobile ears
• Extended head and neck
• “Sawhorse” stance with stiff, extended limbs

Progressive signs:

• Lockjaw (masseter muscle spasm preventing mouth opening)
• Sensitivity to stimuli—sudden noises, touch, or light trigger severe spasms
• Inability to eat or drink
• Respiratory difficulty due to respiratory muscle involvement
• Profuse sweating
• Elevated heart rate
• Eventually, death from respiratory paralysis or exhaustion

Tetanus progresses over days to weeks, causing extreme suffering. Even with intensive treatment (requiring weeks of intensive care in specialized facilities costing tens of thousands of dollars), survival rates remain only 50-75%, and surviving horses often have prolonged recovery periods with residual problems.

Epidemiology: Tetanus occurs worldwide, including throughout the United States. Horses are more susceptible to tetanus than most other species, making prevention particularly critical. The disease occurs sporadically but consistently—cases appear annually across all regions.

Transmission: Not contagious between animals; horses contract tetanus through environmental exposure when wounds become contaminated with C. tetani spores. High-risk situations include:

• Puncture wounds (nails, wire, wood splinters)
• Lacerations and cuts
• Surgical incisions (castration, colic surgery)
• Post-foaling mares (uterine contamination)
• Umbilical infections in foals
• Foot abscesses
• ANY wound, regardless of apparent severity

The Vaccine

Type: Tetanus toxoid (inactivated toxin that stimulates antibody production against the actual toxin)

Efficacy: Extremely high—tetanus toxoid ranks among the most effective vaccines available. Properly vaccinated horses have near-complete protection.

Administration: Intramuscular injection

Primary series:

• Foals from vaccinated mares: Begin at 4-6 months; booster at 10-12 months (completing primary series)
• Foals from unvaccinated mares: Begin at 1-4 months; booster in 4-6 weeks; third dose at 10-12 months
• Previously unvaccinated adults: Initial dose followed by booster in 4-6 weeks

Booster schedule: Annual revaccination maintains protection

Special circumstances:

• Injury in vaccinated horse: If annual booster is current (within 12 months), no additional vaccination needed
• Injury in unvaccinated horse or lapsed vaccination (>12 months): Administer both tetanus toxoid AND tetanus antitoxin (pre-formed antibodies providing immediate temporary protection while immune system responds to toxoid)
• Surgical procedures: Ensure vaccination current before elective surgery; if not current, administer toxoid and consider antitoxin

Side effects:

• Minimal—occasional mild local swelling
• Rarely, transient fever or malaise
• Extremely safe vaccine

Cost: $15-30 per dose (often combined with other vaccines, reducing per-vaccine cost)

Why Tetanus Vaccination is Essential

1. Horses are highly susceptible: More so than most species
2. Ubiquitous organism: C. tetani spores are everywhere in the environment
3. Fatal disease: Extremely high mortality rate despite intensive treatment
4. Preventable wounds occur commonly: Horses routinely sustain minor injuries
5. Treatment is expensive and often unsuccessful: Prevention vastly superior to treatment
6. Highly effective, safe vaccine: Near-complete protection with minimal risk
7. Inexpensive protection: Very low cost relative to disease severity
8. Peace of mind: Eliminates worry when injuries occur

Bottom line: Tetanus toxoid is essential for all horses and represents one of the best investments in equine health care.

3. Eastern Equine Encephalomyelitis (EEE) Vaccine

4. Western Equine Encephalomyelitis (WEE) Vaccine

These two diseases are addressed together as they share similar characteristics, epidemiology, and vaccination recommendations.

The Diseases: EEE and WEE

Eastern and Western Equine Encephalomyelitis are serious, often fatal viral diseases affecting the central nervous system (brain and spinal cord). Both are caused by alphaviruses in the Togaviridae family.

Clinical signs of both diseases are similar:

• High fever (often 105-106°F)
• Depression and decreased awareness
• Head pressing and wandering
• Incoordination and weakness
• Inability to swallow
• Circling, ataxia, or paralysis
• Seizures
• Recumbency (inability to stand)
• Coma and death

EEE is generally more severe than WEE:

• EEE mortality rate: 75-95% of horses showing clinical signs die
• WEE mortality rate: 20-50%
• Both diseases cause permanent neurological damage in many survivors

No specific treatment exists—only supportive care. Even horses that survive often have residual neurological deficits preventing return to previous use.

Epidemiology and Transmission:

These are mosquito-borne diseases with complex transmission cycles:

1. Wildlife reservoir: Viruses circulate between birds (primary hosts) and mosquitoes in wetland environments
2. Mosquito vectors: Specific mosquito species acquire virus from infected birds
3. Transmission to horses: Infected mosquitoes bite horses, transmitting virus
4. Dead-end hosts: Horses (and humans) are “dead-end hosts”—they develop disease but don’t produce sufficient viremia to infect other mosquitoes, so they don’t contribute to transmission cycles

Geographic distribution:

EEE:

• Primarily Eastern United States (Atlantic and Gulf Coast states)
• Focal outbreaks in Atlantic Coast states, Florida, Gulf Coast
• Occasionally appears inland in Great Lakes region
• Highest risk: Late summer and fall (mosquito season)
• Endemic in eastern wetland areas

WEE:

• Primarily Western United States (west of Mississippi River)
• Most common in states including California, Colorado, Texas, and throughout the West
• Also occurs in Central and South America
• Risk period: Summer and early fall
• Less commonly diagnosed than EEE in recent decades (possibly due to effective vaccination programs)

Zoonotic potential: Both EEE and WEE can infect humans, causing similar neurological disease. EEE is particularly dangerous to humans, with high mortality rates. Vaccinating horses reduces overall virus circulation and indirectly protects public health.

The Vaccines

Type: Killed (inactivated) virus vaccines, often combined in a single product

Efficacy: Highly effective—properly vaccinated horses have excellent protection

Administration: Intramuscular injection

Primary series:

• Foals from vaccinated mares: Begin at 4-6 months; booster in 4-6 weeks; third dose at 10-12 months
• Foals from unvaccinated mares: Begin at 3-4 months; booster in 4-6 weeks; third dose at 10-12 months
• Previously unvaccinated adults: Initial dose; booster in 4-6 weeks

Booster schedule:

• Annual revaccination minimum
• Semi-annual vaccination (spring and mid-summer) recommended in:
  • Endemic areas with long mosquito seasons
  • Horses at high risk due to environment (near wetlands, heavy mosquito exposure)
  • Areas with documented disease activity

Side effects:

• Generally minimal
• Occasional local swelling or mild soreness
• Transient low-grade fever (uncommon)
• Serious adverse reactions rare

Cost: Usually included in combination vaccines; approximately $30-50 for EEE/WEE/Tetanus or EEE/WEE/WNV/Tetanus combinations

Why EEE and WEE Vaccination is Essential

1. Fatal diseases with no treatment: Extremely high mortality rates
2. Endemic in many U.S. regions: Risk present throughout large geographic areas
3. Unpredictable outbreaks: Cases occur sporadically; risk difficult to predict
4. Highly effective vaccines: Excellent protection available
5. Mosquito exposure difficult to prevent: Even stabled horses get bitten by mosquitoes
6. Zoonotic concern: Human cases occur; reducing overall disease burden protects communities
7. Legal and ethical responsibility: Failure to vaccinate against preventable fatal disease raises liability concerns

Bottom line: EEE and WEE vaccination is essential for all U.S. horses, with regional variation in timing and frequency based on local mosquito seasons and disease patterns.

5. West Nile Virus (WNV) Vaccine

The Disease: West Nile Virus

West Nile Virus is a mosquito-borne flavivirus that emerged in the United States in 1999 and rapidly spread across the continent, becoming endemic in all 48 contiguous states. WNV causes neurological disease in horses, humans, and birds.

Clinical signs in horses:

• Neurological dysfunction: Ataxia, weakness (particularly hindlimb weakness)
• Behavioral changes: Depression, hyperexcitability, or altered mentation
• Muscle fasciculations (twitching)
• Inability to stand or recumbency
• Head pressing, circling
• Facial paralysis or cranial nerve deficits
• Seizures (less common)
• Coma and death

Severity ranges from mild (subtle incoordination, mild depression) to fatal. Approximately 33% of horses showing clinical signs die or are euthanized. Among survivors, many have permanent neurological deficits.

No specific treatment exists—only supportive care including anti-inflammatory medications, fluid therapy, and nursing care.

Epidemiology:

Transmission cycle: Similar to EEE/WEE

1. Birds (corvids like crows and jays are particularly susceptible) serve as reservoir hosts
2. Mosquitoes acquire virus from infected birds
3. Infected mosquitoes bite horses (and humans), transmitting virus
4. Horses and humans are dead-end hosts

Geographic distribution: Endemic throughout the continental United States, including all 48 contiguous states. Cases occur from coast to coast, though incidence varies regionally and annually.

Seasonal pattern: Peak risk during mosquito season—typically late summer and fall (July through October in most regions), though timing varies by latitude and local climate.

Case numbers: Since WNV’s arrival, thousands of equine cases have been documented annually in the U.S., though effective vaccination programs have reduced incidence significantly compared to early 2000s. Recent years see hundreds to over a thousand cases annually.

Zoonotic significance: WNV causes serious neurological disease in humans, with elderly people at highest risk for severe complications. West Nile is the leading cause of mosquito-borne disease in the United States. Vaccinating horses doesn’t directly protect humans but reduces overall disease awareness and contributes to monitoring systems.

The Vaccine

Type: Multiple vaccine technologies available:

• Killed virus vaccines: Inactivated whole virus
• Recombinant canarypox vector vaccine: Live canarypox virus (which doesn’t replicate in mammals) engineered to express WNV proteins
• DNA vaccine: Bacterial plasmid encoding WNV proteins (approved for WNV but rarely used)

Efficacy: Highly effective—all vaccine types provide excellent protection when properly administered

Administration: Intramuscular injection

Primary series:

• Foals from vaccinated mares: Begin at 4-6 months; booster in 4-6 weeks; third dose at 10-12 months
• Foals from unvaccinated mares: Begin at 3-4 months; booster in 4-6 weeks; third dose at 10-12 months
• Previously unvaccinated adults: Initial dose; booster in 3-6 weeks (timing varies by product)

Booster schedule:

• Annual revaccination minimum
• Semi-annual vaccination recommended for high-risk horses in endemic areas
• Optimal timing: Spring (before mosquito season) with optional fall booster

Side effects:

• Generally well-tolerated
• Mild local swelling or soreness occasionally
• Transient fever or lethargy (uncommon)
• Serious adverse reactions rare

Cost: $30-50 per dose (often in combination vaccines)

Why West Nile Virus Vaccination is Essential

1. Endemic throughout U.S.: Present in all contiguous states
2. Serious disease: High mortality and morbidity rates
3. No treatment available: Prevention is only protection
4. Unpredictable individual risk: Any horse exposed to mosquitoes is at risk
5. Highly effective vaccines: Excellent protection available
6. Public health awareness: Leading mosquito-borne disease in humans
7. Proven vaccination impact: Areas with high vaccination rates show reduced equine case numbers

Bottom line: West Nile Virus vaccination is essential for all horses in the United States, constituting the fifth core vaccine.

Risk-Based Vaccines: Conditional Recommendations

The following vaccines protect against diseases where vaccination recommendations depend on individual circumstances, geographic location, exposure risk, and specific management factors. Decisions should be made in consultation with your veterinarian based on your situation.

1. Influenza Vaccine

The Disease: Equine Influenza

Equine influenza is a highly contagious respiratory disease caused by influenza A viruses (subtypes H3N8 and H7N7, though H7N7 has not been isolated recently).

Clinical signs:

• Sudden onset high fever (102-106°F)
• Harsh, dry cough (often severe and painful-sounding)
• Copious nasal discharge (initially watery, becoming mucopurulent)
• Depression and lethargy
• Decreased appetite
• Enlarged lymph nodes
• Muscle soreness

Uncomplicated cases typically resolve within 2-3 weeks with rest. Complications include:

• Secondary bacterial pneumonia (potentially serious)
• Chronic airway inflammation affecting future performance
• Myocarditis (heart muscle inflammation) if horses exercise during illness

Transmission: Highly contagious—spreads rapidly through airborne droplets when infected horses cough. The virus can spread over considerable distances in aerosol form. Incubation period is short (1-3 days), and horses begin shedding virus before showing obvious signs, facilitating rapid outbreak spread.

Epidemiology: Influenza occurs worldwide. In the U.S., outbreaks occur sporadically, often associated with:

• Horse shows and competitions
• Sales and auctions
• Training facilities
• Racetracks
• Any gathering of horses from multiple sources

Young horses (weanlings to 3 years) are most susceptible, though any horse can be infected if not immune.

The Vaccine

Type:

• Killed (inactivated) virus vaccines: Most common
• Modified-live intranasal vaccine: Available but less commonly used

Efficacy: Moderate to good

• Reduces disease severity and viral shedding
• May not prevent infection entirely, particularly with antigenically mismatched strains
• Immunity duration relatively short (3-6 months)

Administration: Intramuscular injection (killed vaccines) or intranasal (MLV)

Primary series:

• Foals: Initial dose at 6 months; booster in 4-6 weeks; third dose at 10-12 months
• Previously unvaccinated adults: Two doses 4-6 weeks apart

Booster schedule (varies by risk):

• High-risk horses (show horses, racehorses, frequently traveling): Every 3-6 months
• Moderate-risk horses: Every 6 months
• Low-risk horses: Annually or as needed before exposure risk situations

Side effects:

• Mild local swelling common
• Occasional low-grade fever or lethargy for 24-48 hours
• Rarely, more significant reactions

Cost: $25-40 per dose

Recommendations

Consider vaccinating:

• Performance horses (show, race, eventing, endurance, etc.)
• Horses frequently traveling or exposed to transient horses
• Horses at boarding facilities with regular turnover
• Young horses (particularly susceptible)
• Breeding stock on farms with frequent visitors

May not need vaccination:

• Isolated horses with no contact with outside horses
• Retired or companion horses without travel or show exposure
• Horses in small, closed herds with no new additions

Special considerations:

• Many competitions require proof of influenza vaccination
• Consider timing vaccinations before shows/travel (ideally 2+ weeks before for optimal immunity)
• Balance frequency based on true exposure risk vs. cost and convenience

2. Equine Herpesvirus (EHV) / Rhinopneumonitis Vaccine

The Diseases: Equine Herpesvirus

Equine herpesvirus encompasses several viruses, primarily EHV-1 and EHV-4. These viruses cause:

Respiratory disease (rhinopneumonitis):

• Fever, nasal discharge, cough
• Usually mild to moderate severity
• More significant in young horses
• Both EHV-1 and EHV-4 cause respiratory disease

Abortion in pregnant mares:

• EHV-1 causes abortion (typically late-term, after 7 months gestation)
• Abortions may occur as “abortion storms” affecting multiple mares
• Mares often show no preceding illness

Neurological disease (EHM – Equine Herpesvirus Myeloencephalopathy):

• EHV-1 (specific neuropathogenic strains) causes devastating neurological disease
• Sudden onset ataxia, weakness, urinary incontinence
• Can progress to paralysis and recumbency
• Mortality rate significant; survivors may have permanent deficits
• Highly sporadic and unpredictable

Epidemiology:

• Extremely common: Most horses are infected with EHV-1 and/or EHV-4 during their lives
• Virus establishes latent infection (dormant in nerve cells), periodically reactivating and shedding
• Spreads through respiratory secretions and contact with aborted fetuses/placental material
• Outbreaks common in high-density populations

The Vaccines

Type: Killed (inactivated) virus vaccines; modified-live vaccines previously available but no longer marketed in U.S.

Efficacy: Moderate to limited

• Reduces severity of respiratory disease
• May reduce but does NOT eliminate abortion risk
• Does NOT reliably prevent neurological disease
• Immunity duration short (3-4 months)

Important limitation: Current vaccines provide incomplete protection, particularly against abortion and neurological manifestations.

Administration: Intramuscular injection

Primary series:

• Foals/young horses: Initial dose at 6 months; booster in 4-6 weeks; additional doses at 10-12 months
• Adults: Two-dose initial series

Booster schedule:

• Pregnant mares (abortion prevention protocol): Vaccinate during 5th, 7th, and 9th months of gestation
• Performance horses: Every 3-6 months
• Other horses: Every 6-12 months based on risk

Side effects: Generally mild; occasional local swelling or low-grade fever

Cost: $25-40 per dose

Recommendations

Consider vaccinating:

• Pregnant mares on breeding farms (following specific protocol for abortion prevention)
• Performance horses with high exposure risk
• Young horses (respiratory disease more significant)
• Horses on large facilities with many horses and regular introductions

Limited utility for:

• Preventing neurological disease (vaccines not reliably protective)
• Individual horses in closed herds with low exposure risk

Important considerations:

• Even vaccinated mares can abort
• Vaccination one component of biosecurity; isolation of new arrivals, hygiene, and quarantine measures equally important
• Some experts question widespread EHV vaccination in low-risk horses due to limited efficacy

3. Strangles Vaccine

The Disease: Strangles

Strangles, caused by Streptococcus equi subspecies equi, is covered extensively in a previous section but briefly:

• Highly contagious bacterial upper respiratory infection
• Characterized by fever, nasal discharge, and abscessation of lymph nodes
• Potentially serious complications including purpura hemorrhagica, metastatic abscesses
• Most horses recover but disease causes significant morbidity

The Vaccines

Types available:

1. Intramuscular (injectable) vaccines: Killed or modified-live bacterial products
2. Intranasal vaccine: Modified-live attenuated S. equi

Efficacy: Moderate to limited

• Reduces disease severity more than preventing infection
• Approximately 50-75% reduction in clinical disease
• Does NOT reliably prevent infection, particularly with high challenge doses
• Duration of immunity unclear

Adverse reactions: Higher than most vaccines

• Injectable vaccines: Significant risk of local abscess formation at injection sites (neck swellings)
• Can trigger purpura hemorrhagica (rare but serious)
• Intranasal vaccine: Generally milder reactions; occasional nasal discharge or lymph node swelling

Administration:

• Injectable: Intramuscular (though due to abscess risk, avoid neck; use pectoral muscles)
• Intranasal: Into nostrils

Primary series: Typically 2-3 doses spaced 2-4 weeks apart

Boosters: Annually or semi-annually in high-risk horses

Cost: $35-60 per dose

Recommendations

Consider vaccinating:

• Young horses (weanlings, yearlings) at high-risk facilities (training barns, show barns with frequent new arrivals)
• Horses frequently traveling to shows, sales, or other high-risk venues
• Facilities with endemic strangles problems

Generally NOT recommended for:

• Low-risk horses (home horses, closed herds)
• During outbreaks (do NOT vaccinate sick or exposed horses)
• Horses recently recovered from strangles (already have natural immunity)

Important considerations:

• Controversial vaccine due to efficacy limitations and side effect risk
• Many veterinarians recommend intranasal vaccine over injectable due to better side effect profile
• Biosecurity more important than vaccination for strangles prevention
• Vaccination may complicate serological testing (causes positive antibody titers)

Bottom line: Risk-benefit analysis needed; many horses don’t require strangles vaccination.

4. Potomac Horse Fever (PHF) Vaccine

The Disease: Potomac Horse Fever

Potomac Horse Fever (equine monocytic ehrlichiosis) is caused by Neorickettsia risticii, an intracellular bacterium transmitted through aquatic insects.

Clinical signs:

• Fever (often high, 102-107°F)
• Depression and decreased appetite
• Diarrhea (often profuse, watery)
• Colic signs
• Laminitis (develops in 20-40% of cases, often severe)
• Dehydration and shock in severe cases

Mortality rate: 5-30% depending on severity and treatment timeliness

Epidemiology:

• Geographic distribution: Originally identified along Potomac River in Maryland/Virginia but occurs throughout U.S., particularly:
  • Mid-Atlantic and Northeastern states
  • Midwest
  • Pacific Northwest
  • Near rivers, streams, and irrigated pastures
• Seasonal: Late summer and fall (July-October) primarily
• Transmission: Horses ingest aquatic insects (mayflies, caddisflies) harboring the bacterium; NOT contagious between horses

The Vaccine

Type: Killed whole-cell bacterin

Efficacy: Limited

• Provides incomplete protection (estimated 50-80% reduction in clinical disease severity)
• Does NOT reliably prevent infection
• Duration of immunity short (3-4 months)
• Vaccine strain may not match circulating strains in all areas

Administration: Intramuscular injection

Primary series: Two doses 3-4 weeks apart

Boosters:

• Every 6 months in endemic areas
• Optimally time to provide coverage during risk season (early summer and fall)

Side effects: Mild; occasional local swelling

Cost: $30-45 per dose

Recommendations

Consider vaccinating:

• Horses in endemic areas (particularly Mid-Atlantic, Midwest, Pacific Northwest)
• Horses near rivers, streams, or irrigated pastures
• Areas with documented disease occurrence
• Summer and fall booster timed for peak risk season

Probably NOT necessary:

• Horses in areas where disease has never been documented
• Horses without exposure to aquatic environments
• Regions outside endemic zones

Important notes:

• Even vaccinated horses can contract PHF
• Prompt recognition and treatment critical regardless of vaccination status
• Some veterinarians question widespread PHF vaccination due to limited efficacy and cost

Bottom line: Discuss regional disease prevalence with your veterinarian; valuable in endemic areas, unnecessary elsewhere.

5. Additional Risk-Based Vaccines

Several additional vaccines are available for specific circumstances:

Botulism Vaccine

Disease: Botulism caused by Clostridium botulinum toxins; causes progressive paralysis and death

Vaccine indications:

• Foals in areas where shaker foal syndrome (Type B botulism) is endemic (primarily Mid-Atlantic states, Kentucky)
• Pregnant mares on endemic farms (vaccinate during pregnancy to provide passive immunity to foals)

Not needed: Outside endemic areas or for adult horses not breeding

Anthrax Vaccine

Disease: Anthrax caused by Bacillus anthracis; rapidly fatal disease causing sudden death

Vaccine indications:

• Horses in areas with documented anthrax outbreaks
• Very localized geographic occurrence in U.S. (certain areas of Texas, Louisiana, and other states with endemic zones)

Not needed: Outside areas with known anthrax risk

Equine Viral Arteritis (EVA) Vaccine

Disease: EVA causes respiratory disease, abortion, and illness in young foals

Vaccine indications:

• Breeding stallions (particularly those at commercial breeding facilities or standing at stud)
• Horses traveling internationally (some countries require EVA testing/vaccination)

Important: Stallions should be tested before vaccination (vaccination causes positive antibody titers complicating interpretation)

Not needed: Most non-breeding horses

Rotavirus Vaccine

Disease: Rotavirus causes diarrhea in foals

Vaccine indications:

• Pregnant mares on breeding farms with rotavirus problems
• Vaccinate during late pregnancy (8th, 9th, and 10th months) to produce antibodies in colostrum

Not needed: Non-breeding horses or farms without rotavirus issues

Creating a Vaccination Schedule

Developing an effective vaccination program requires considering multiple factors and working with your veterinarian.

Basic Annual Schedule for Most Adult Horses

A typical annual vaccination protocol might include:

Spring (March-April):

• Tetanus
• EEE/WEE
• West Nile Virus
• Rabies
• Influenza (if indicated)
• EHV (if indicated)

Fall (September-October) – for horses requiring semi-annual vaccines:

• EEE/WEE booster (in endemic areas or high-risk horses)
• West Nile Virus booster (high-risk horses)
• Influenza booster (performance horses)
• PHF booster (if indicated)

Important timing considerations:

• Before mosquito season: Vaccinate for EEE/WEE/WNV at least 2 weeks before mosquitoes become active
• Before show season: Vaccinate performance horses for influenza/EHV at least 2-3 weeks before competitions begin
• Before breeding season: Pregnant mares follow specific protocols for EHV, botulism (if indicated)

Foal Vaccination Programs

Foals from vaccinated mares:

• 3-4 months: Begin strangles (if high risk)
• 4-6 months: Tetanus, EEE/WEE, WNV, rabies, influenza (initial doses)
• 8-10 months: Boosters (2nd doses of primary series)
• 10-12 months: Final doses of primary series

Foals from unvaccinated mares or unknown status:

• Begin earlier (3-4 months for most vaccines)
• Earlier rabies (3-4 months)
• More aggressive schedule due to lack of maternal antibody protection

New Horse Recommendations

When acquiring a new horse with unknown vaccination history:

1. Assume unvaccinated and begin complete primary series
2. Core vaccines: All five core vaccines with appropriate booster timing
3. Risk-based vaccines: Based on horse’s intended use and environment
4. Quarantine period: Consider vaccinating during quarantine before introducing to resident horses

Special Populations

Pregnant mares:

• Continue core vaccines
• EHV-1 protocol: 5th, 7th, 9th months of gestation
• Botulism (if indicated): 8th, 9th, 10th months
• Rotavirus (if indicated): 8th, 9th, 10th months

Senior horses:

• Continue all core vaccines
• May have diminished immune response; maintain consistent schedule
• Monitor for adverse reactions (though serious reactions remain rare)

Performance horses:

• More frequent boosters (particularly influenza/EHV)
• Coordinate with competition schedule
• Verify venue requirements (many require specific vaccines and documentation)

Vaccine Administration and Safety

Proper Administration

Vaccines should be administered by or under supervision of licensed veterinarians to ensure:

• Proper storage and handling (vaccines require refrigeration; temperature excursions destroy efficacy)
• Correct administration technique
• Appropriate recordkeeping
• Management of adverse reactions if they occur

Administration sites:

• Generally given in neck or hindquarter muscles
• Some vaccines (tetanus, strangles) may be given in pectoral muscles to reduce neck swelling concerns
• Intranasal vaccines require specific technique

Side Effects and Adverse Reactions

Common, mild reactions:

• Local swelling or soreness at injection site (24-72 hours)
• Low-grade fever (may last 24-48 hours)
• Temporary decreased appetite or lethargy

Manage by:

• Monitor; usually resolve without intervention
• Apply cool compresses to injection sites if swollen
• NSAIDs if discomfort significant

Serious reactions (rare):

• Anaphylaxis (severe allergic reaction): Difficulty breathing, collapse, hives
  • Emergency requiring immediate veterinary intervention
  • Extremely rare but life-threatening
• Purpura hemorrhagica: Immune-mediated vasculitis causing severe swelling
  • Associated particularly with strangles vaccines
  • Requires aggressive treatment
• Clostridial myonecrosis: Severe muscle infection at injection site
  • Very rare, associated with contamination
  • Requires immediate aggressive treatment

Best Practices

• Don’t vaccinate sick horses: Delay vaccination until recovered from illness
• Avoid vaccinating stressed horses: After transport, surgery, or other major stressors
• Space vaccines: If giving multiple vaccines, use different injection sites
• Record keeping: Maintain records of all vaccinations including product names, dates, and adverse reactions
• Time before events: Vaccinate at least 2-3 weeks before shows, competitions, or travel when possible

Cost Considerations

Vaccination costs vary based on:

• Geographic location
• Number of horses
• Farm/ambulatory fees vs. clinic visits
• Products selected (combination vs. individual vaccines)

Estimated annual costs per horse (veterinary exam fees additional):

• Core vaccines only (5 vaccines, annual): $150-250
• Core vaccines with semi-annual EEE/WEE/WNV: $200-300
• Performance horse program (core + influenza + EHV, multiple boosters): $300-450+

Cost-saving strategies:

• Combination vaccines: Multi-valent products reduce per-vaccine cost
• Group appointments: Having multiple horses vaccinated during one veterinary visit reduces overall farm call fees
• Wellness plans: Some veterinary practices offer vaccination packages
• Owner administration: In some states, owners can purchase and administer vaccines (though veterinary oversight recommended)

Cost vs. benefit: Even expensive vaccination programs cost far less than treating vaccine-preventable diseases (ICU care for tetanus, EEE, or WNV can cost $10,000-50,000+ with uncertain outcomes).

Common Questions and Misconceptions

“My horse lives alone at home. Does he really need vaccines?”

Yes, absolutely core vaccines. Even isolated horses face rabies exposure (bats enter buildings), tetanus (environmental contamination), and mosquito-borne diseases (mosquitoes find horses anywhere). Risk-based vaccines may not be needed for truly isolated horses.

“Can I just vaccinate once and be done?”

No. Immunity wanes over time. Annual boosters (or more frequent for some vaccines) are necessary to maintain protection.

“My horse had a reaction last time. Should I skip vaccines?”

Mild reactions (soreness, low fever) are not reasons to discontinue vaccination. Discuss with your veterinarian—pre-treatment with anti-inflammatories, splitting vaccines into multiple visits, or switching products may help. True severe allergic reactions are extremely rare and may warrant modified protocols.

“I’ve never vaccinated and my horses have been fine.”

This reflects luck, not immunity. Unvaccinated horses remain susceptible and are at risk when exposed. Additionally, failure to vaccinate creates liability concerns and isn’t fair to the horse when simple prevention exists.

“Natural immunity is better than vaccines.”

“Natural immunity” requires surviving potentially fatal diseases. Vaccines provide protection without disease risks. This is particularly relevant for diseases like tetanus and rabies with >90% mortality rates.

“Vaccines cause disease.”

Modern vaccines cannot cause disease. Killed vaccines contain dead organisms. Even modified-live vaccines use attenuated (weakened) organisms that cannot cause disease in immunocompetent horses. Coincidental timing (horse developing illness shortly after vaccination) is not causation.

Conclusion

Vaccination represents a cornerstone of responsible horse ownership and preventive health care. The five core vaccines—rabies, tetanus, EEE, WEE, and West Nile Virus—protect against serious, often fatal diseases endemic throughout the United States and should be administered to all horses regardless of use, location, or lifestyle, with only rare medical contraindications justifying exceptions.

Risk-based vaccines—including influenza, equine herpesvirus, strangles, Potomac Horse Fever, and others—provide additional protection for horses whose specific circumstances create elevated disease risk. Decisions about risk-based vaccines should be made individually through discussion with your veterinarian, considering your horse’s age, use, travel patterns, facility characteristics, and regional disease prevalence.

An effective vaccination program requires:

• Proper primary vaccination series establishing initial immunity
• Consistent annual (or more frequent) boosters maintaining protection
• Appropriate timing based on seasonal disease patterns and horse use
• Complete recordkeeping documenting all vaccinations
• Veterinary oversight ensuring proper vaccine handling, administration, and adverse reaction management

While vaccination cannot provide 100% guaranteed protection, properly administered vaccine programs dramatically reduce disease incidence, minimize severity when breakthrough infections occur, and represent the most cost-effective approach to protecting horses from preventable infectious diseases. The modest investment in annual vaccinations pales in comparison to the catastrophic costs—both financial and emotional—of treating vaccine-preventable diseases, many of which are fatal despite intensive care.

Working with your veterinarian to develop and implement an individualized vaccination program tailored to your horses’ specific needs, circumstances, and risk factors provides optimal protection while avoiding unnecessary vaccinations. This partnership approach to preventive medicine optimizes horse health, enhances welfare, and fulfills the ethical and practical responsibilities of horse ownership.